Clinical trial · no report yet · Phase 2
CaboPoint
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
- NCT03945773 ↗
- Completed
- Ipsen
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 20 | |
| YouTube | 8 | |
| Podcasts | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Locally Advanced or Metastatic Renal Cell Carcinoma
- Interventions
- Cabozantinib
- Arms
- Cohort A · Experimental
- Cohort B · Experimental
- Enrollment
- 127
- Primary outcomes
- Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review
- Sponsor
- Ipsen
- Start
- Jan 8, 2020
- Primary completion
- May 11, 2023
- Results posted
- Yes
- Registry record
- NCT03945773 · updated Oct 6, 2026
Publications
linked from the registry- Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grunwald V, Guemas E. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2022 Mar;18(8):915-926. doi: 10.2217/fon-2021-1006. Epub 2021 Dec 16. PubMed 34911359